Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talabostat and Rituximab in Advanced CLL
NCT00086203Phase 2Completed
- Sponsor
- Point Therapeutics
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of talabostat in chronic lymphocytic leukemia (CLL), sponsored by Point Therapeutics. Status: completed.
02
Drugs
talabostat
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00086203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00086203.